Iterum Therapeutics PLC (NASDAQ:ITRM) Stock Soars 61% After Approval of ORLYNVAH™

October 28, 2024

This morning investors are going to look into those stocks that may have clocked strong gains last Friday, and one of the stocks that could be in focus is that of Iterum Therapeutics PLC (NASDAQ:ITRM). Following an announcement from the company, the stock soared by 61% for the day.  Product Approval On Friday, the company announced that its new drug ORLYNVAH had been approved by the United States Food and…

Read More >>

Iterum Therapeutics Plc (NASDAQ:ITRM) Stock Falls Ahead of Quarterly Earnings

November 8, 2021

Clinical stage pharmaceutical firm Iterum Therapeutics Plc (NASDAQ:ITRM) did not have a particularly great time in the capital markets this past Friday and its stock ended the day with a decline of as much as 4%. Trading Data On Friday, ITRM stock fell 4% at $0.5640 with more than 3.57 million million shares, compared to its average volume of 5.43 million shares. The stock has moved within a range of…

Read More >>